Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases.
Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments.
These unique drug candidates, by reproducing a recently discovered natural defense mechanism of the brain , appear to be able to treat various brain pathologies without disrupting normal behavior. A first in pharmacology.
Two initial drug candidates are already in clinical trials in indications with high unmet medical needs:
• AEF0117, to treat disorders due to excessive cannabis use, has already provided evidence of efficacy in a phase 2a clinical study and has entered a phase 2b clinical trial in Q2 2022.
• AEF0217, to treat various cognitive deficits, including those associated with Down syndrome (Trisomy 21), is currently being evaluated in phase 1 clinical trials, with no major adverse effects observed in the three patient cohorts treated to date. Phase 1/2 clinical studies with AEF0217 in Down syndrome subjects are expected to start in Q4 2022. These studies could provide initial efficacy results in H1 2023.
Given the involvement of the CB1 receptor in numerous pathologies, Aelis Farma is also developing using its proprietary platform, several new CB1-SSi with differentiated pharmacological properties to target other brain pathologies.
Based in Bordeaux, within the Inserm Magendie Neurocentre, Aelis Farma has a team of 24 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and IRDI Capital Investissement.
Company Details
- Employees
- 29
- Founded
- -
- Address
- 1, Rue Lafaurie De Monbadon, Bordeaux,nouvelle-Aquitaine 33000,france
- Phone
- +33 5 57 57 37 70
- co****@****rma.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.aelisfarma.com
- Keywords
- Biotechnology, Central Nervous System, Innovative signaling specific drugs, CB1 receptor, Allosteric modulator, Cannabis addiction, Cognitive Disorders, Down syndrome, Fragil X syndrom, obesity, metabolic disorders, cannabis use disorders.
- HQ
- Bordeaux, Nouvelle-Aquitaine
Aelis Farma Questions
Aelis Farma's helpline number is +33 5 57 57 37 70
Aelis Farma's website is http://www.aelisfarma.com
Aelis Farma's LinkedIn profile is https://fr.linkedin.com/company/aelis-farma
Aelis Farma has
29 employees.
View email and phone details for 29
employees at Aelis Farma.
Aelis Farma's industry is
Biotechnology Research
Aelis Farma's top competitors are
Olon France,
Novaptech,
Innate Pharma,
Ambiotis,
Treefrog Therapeutics,
Cell-Easy,
Antabio,
Dendris,
Imavita,
Ysopia Bioscience.
Aelis Farma's support email address is contact@aelisfarma.com
Aelis Farma's categories are Biotechnology Research
Aelis Farma's founding year is 2013
